Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy

Medical Oncology

Volumn 21, Issue 3, 2004, Pages 211-215

  Altundag, Kadri ^a,b   Aksoy, Sercan ^a   Gullu, Ibrahim ^a   Altundag, Ozden ^a   Ozyar, Enis ^a   Yalcin, Suayib ^a   Cengiz, Mustafa ^a   Akyol, Fadil ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (United States)

Author keywords

Adriamycin; Chemotherapy; Ifosfamide; Nasopharyngeal carcinoma; Recurrent

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PLATINUM DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELIRIUM; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; MALE; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTE TRANSFUSION; TUMOR CELL DESTRUCTION;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CISPLATIN; COMBINED MODALITY THERAPY; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SOFTWARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 7944235455     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:3:211     Document Type: Article

References (20)

1. Fandi A, Atum M, AzIi N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994; 21:382-397.
2. Vaughan TL, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 1996; 5:587-593.
3. World Health Organization. International classification of tumors: histological typing of upper respiratory tract tumors. Geneva: World Health Organization, 1991.
4. Lee AW, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23:261-270.
5. Perez CA, et al. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992; 23:271-280.
6. Teo ML, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastases from nasopharyngeal carcinoma. Cancer 1996; 77:2423-2431.
7. Fandi A, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of the nasopharyngeal type. J Clin Oncol 2000;18:1324-1330.
8. Chua DTT, Kwong DLW, Sham JST, Au GKH, Choy D. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer 2000; 36:736-741.
9. Foo KF, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13:150-156.
10. Yeo W, et al. A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998; 34:2027-2031.
11. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002; 95:2516-2523.
12. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003; 39:361-366.
13. Huang HQ, et al. Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma (Article in Chinese). Ai Zheng 2002; 21:409-411.
14. McCarthy JS, et al. A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma Oral Oncol 2002; 38:686-690.
15. Azli N, et al. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am 1995; 1:222.
16. Hasbini A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol 1999; 10:421-425.
17. Taamma A, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 1999; 86:1101-1108.
18. Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 1998; 16:2514-2521.
19. Onat H, et al. High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol) 2002; 14:449-454.
20. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979